A detailed history of Arizona State Retirement System transactions in Ardelyx, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 67,372 shares of ARDX stock, worth $323,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,372
Previous 65,141 3.42%
Holding current value
$323,385
Previous $482,000 3.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.28 - $7.57 $11,779 - $16,888
2,231 Added 3.42%
67,372 $464,000
Q2 2024

Aug 05, 2024

BUY
$5.89 - $9.31 $7,916 - $12,512
1,344 Added 2.11%
65,141 $482,000
Q1 2024

May 07, 2024

BUY
$6.05 - $9.74 $17,514 - $28,197
2,895 Added 4.75%
63,797 $465,000
Q4 2023

Jan 24, 2024

SELL
$3.29 - $6.64 $532 - $1,075
-162 Reduced 0.27%
60,902 $377,000
Q3 2023

Nov 06, 2023

BUY
$3.3 - $4.83 $10,111 - $14,799
3,064 Added 5.28%
61,064 $249,000
Q2 2023

Aug 01, 2023

BUY
$3.23 - $4.95 $29,441 - $45,119
9,115 Added 18.65%
58,000 $196,000
Q1 2023

Apr 27, 2023

BUY
$2.68 - $4.79 $131,011 - $234,159
48,885 New
48,885 $234,000
Q4 2021

Feb 04, 2022

SELL
$0.86 - $1.7 $13,874 - $27,426
-16,133 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$1.27 - $8.17 $1,795 - $11,552
1,414 Added 9.61%
16,133 $21,000
Q2 2021

Aug 02, 2021

SELL
$6.55 - $8.98 $15,438 - $21,165
-2,357 Reduced 13.8%
14,719 $112,000
Q1 2021

May 06, 2021

BUY
$6.1 - $7.69 $1,634 - $2,060
268 Added 1.59%
17,076 $113,000
Q4 2020

Jan 28, 2021

SELL
$5.05 - $7.1 $3,322 - $4,671
-658 Reduced 3.77%
16,808 $109,000
Q3 2020

Nov 05, 2020

BUY
$5.25 - $7.08 $23,199 - $31,286
4,419 Added 33.87%
17,466 $92,000
Q2 2020

Aug 04, 2020

BUY
$5.37 - $8.11 $70,062 - $105,811
13,047 New
13,047 $90,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $742M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.